Evidence Explorer · MS-N221 · Nutrition support and omega-3 formulations · Appraised November 3, 2026
In advanced pancreatic cancer with cachexia, an EPA-enriched high-protein, high-energy drink did not outperform an isocaloric, isonitrogenous control drink in the intention-to-treat comparison. Post-hoc dose-response findings are exploratory.
Evidence at a glance
Benefit signal: No added benefit at the amount participants actually consumed
Certainty: Moderate for no between-group weight or lean-mass advantage over eight weeks
Risk context: Poor intake and taste burden can limit adherence; formula-specific tolerance matters
What was studied
The multicenter double-blind trial randomized 200 people (95 EPA formula, 105 control) to two cans daily for eight weeks. Both provided 620 kcal and 32 g protein; the experimental formula added 2.2 g EPA per prescribed daily dose.
Average intake was only 1.4 cans daily. Both groups stopped losing weight to a similar degree: change in weight −0.25 versus −0.37 kg/month (P=0.74), and lean body mass +0.27 versus +0.12 kg/month (P=0.88). Dose-response correlations favoring the EPA formula were post hoc.
What this evidence cannot establish
This compares two calorie- and protein-containing supplements; it does not show that either is better than individualized food-first care or establish a general omega-3 effect.
Weight stabilization is supportive care, not evidence of tumor shrinkage, longer survival or improved treatment response.
Practical safety context
Pancreatic cancer may require pancreatic-enzyme adjustment, diabetes management and symptom-directed diet changes. Fish-derived products can cause taste, reflux or gastrointestinal problems and may be unsuitable with allergy.
High-dose omega-3 products can affect bleeding risk in some settings; formulation and total intake should be reviewed before procedures or with anticoagulants.
Questions for the care team
- Is the main problem low intake, malabsorption, inflammation or inadequate pancreatic enzymes?
- Can I reliably consume the studied volume without worsening nausea or fullness?
- What objective goal—weight, strength, intake or treatment tolerance—will we monitor?
Sources
- Multicenter randomized double-blind trial (PMID 12970142)
Sources and publication status checked November 3, 2026. Full text was available; the intention-to-treat comparison, not the post-hoc dose-response analysis, drives the conclusion.
For education, not personal medical advice. Nutrition and supplement decisions during cancer care should be individualized with the oncology and dietetics teams.
